Vimian Group (VIMIAN) Q4 2024 earnings summary

Executive summary

• Achieved record Q4 2024 revenue of EUR 104.9 million, up 27% year-over-year, with 15% organic growth, driven by Specialty Pharma, Veterinary Services, and the iM3 acquisition.

• Strong cash flow from operations, with EUR 24.4 million in Q4 and EUR 58.1 million for the full year, and a 115% cash conversion ratio in Q4.

• Successfully integrated iM3, contributing EUR 10.1 million in Q4 revenue and expanding into the veterinary dental market.

• Set new financial targets, completed a rights issue, and strengthened the balance sheet.

• All segments contributed to growth, despite MedTech US market headwinds and ongoing legal costs.

Financial highlights

• Q4 2024 revenue rose 27% year-over-year to EUR 104.9 million, with 15% organic growth and 12% from acquisitions.

• Adjusted EBITA grew 9% year-over-year in Q4 to EUR 24.6 million (23.4% margin), with operating profit at EUR 12.5 million, up from EUR 2.7 million.

• Net profit for Q4 was EUR 12.5 million, with EPS of EUR 0.02.

• Cash flow from operating activities was EUR 24.4 million in Q4, up from EUR 17.2 million year-over-year.

• Net debt at year-end was EUR 221.9 million, with leverage at 2.0x Net Debt/LTM Proforma Adj. EBITDA.

Outlook and guidance

• Entering 2025 with a strong foundation, expecting continued strong organic growth and operational improvements, with MedTech segment facing a Q1 decline due to AOP phase-out but full-year recovery expected.

• Diagnostics and Specialty Pharma expected to remain growth businesses in 2025, with positive margin outlooks.

• Price increases for 2025 expected to be low to mid-single digits, with a cautious approach in US MedTech.

• Board proposes no dividend for 2024.